Evidence map›Paper›PMID 25539624›Full record

ArticleHeart and vessels2016

Correlations of the changes in bioptic findings with echocardiographic, clinical and laboratory parameters in patients with inflammatory cardiomyopathy.

Jan Krejci, Petr Hude, Hana Poloczkova, Vita Zampachova, Radka Stepanova, Tomas Freiberger, Eva Nemcova, Lenka Spinarova

Abstract read
PubMed Publisher
In one paragraph

Article in Heart and vessels, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Jan KrejciDepartment of Cardiovascular Diseases, St. Anne's University Hospital, International Clinical Research Center, Pekarska 53, 65690, Brno, Czech Republic. jan.krejci@fnusa.cz.
Petr HudeDepartment of Cardiovascular Diseases, St. Anne's University Hospital, International Clinical Research Center, Pekarska 53, 65690, Brno, Czech Republic.
Hana PoloczkovaDepartment of Cardiovascular Diseases, St. Anne's University Hospital, International Clinical Research Center, Pekarska 53, 65690, Brno, Czech Republic.
Vita ZampachovaMasaryk University, Brno, Czech Republic.
Radka StepanovaInternational Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic.
Tomas FreibergerCentre for Cardiovascular Surgery and Transplantation, Brno, Czech Republic.
Eva NemcovaInternational Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic.
Lenka SpinarovaDepartment of Cardiovascular Diseases, St. Anne's University Hospital, International Clinical Research Center, Pekarska 53, 65690, Brno, Czech Republic.
St. Anne's University Hospital Brno · CZCentrum kardiovaskulární a transplantační chirurgie · CZMasaryk University · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with myocarditis and left ventricular (LV) dysfunction may improve after standard heart failure therapy. This improvement seems to be related to retreat of myocardial inflammation. The aim of the present study was to assess changes in clinical, echocardiographic and some laboratory parameters and to correlate them with changes in the number of inflammatory infiltrating cells in endomyocardial biopsy (EMB) samples during the 6-month follow-up, and to define predictors of LV function improvement among baseline parameters. Forty patients with biopsy-proven myocarditis and impaired LV function (LV ejection fraction-LVEF <40 %) with heart failure symptoms ≤ 6 months were evaluated. Myocarditis was defined as the presence of >14 mononuclear leukocytes/mm(2) and/or >7 T-lymphocytes/mm(2) in the baseline EMB. The EMB, echocardiography and clinical evaluation were repeated after 6 months of standard heart failure therapy. LVEF improved on average from 25 ± 9 to 42 ± 12 % (p < 0.001); LV end-systolic volume and LV end-diastolic volume (LVEDV) decreased from 158 ± 61 to 111 ± 58 ml and from 211 ± 69 to 178 ± 63 ml (both p < 0.001). NYHA class decreased from 2.6 ± 0.5 to 1.6 ± 0.6 (p < 0.001) and NTproBNP from 2892 ± 3227 to 851 ± 1835 µg/ml (p < 0.001). A decrease in the number of infiltrating leukocytes (CD45+/LCA+) from 23 ± 15 to 13 ± 8 cells/mm(2) and in the number of infiltrating T lymphocytes (CD3+) from 7 ± 5 to 4 ± 3 cells/mm(2) (both p < 0.001) was observed. The decline in the number of infiltrating CD45+ cells significantly correlated with the change in LVEF (R = -0.43; p = 0.006), LVEDV (R = 0.39; p = 0.012), NYHA classification (R = 0.35; p = 0.025), and NTproBNP (R = 0.33; p = 0.045). The decrease in the number of CD3+ cells correlated with the change of systolic and diastolic diameters of the left ventricle (R = -0.33; p = 0.038 and R = -0.45; p = 0.003) and with the change in LVEDV (R = -0.43; p = 0.006). Tricuspid annular plane systolic excursion (TAPSE) (OR 0.61; p = 0.005) and early transmitral diastolic flow velocity (E wave) (OR 0.89; p = 0.002) were identified as predictors of LVEF improvement. Improvements in clinical status, LV function and NTproBNP levels correlated with decrease in the number of infiltrating inflammatory cells. TAPSE and E wave velocity were significant predictors of improvement in multivariate regression. Our observations suggest that contemporary guidelines-based therapy of heart failure is an effective treatment option in patients with recent onset biopsy-proven inflammatory cardiomyopathy.

Indexed as

Echocardiography, DopplerStroke VolumeVentricular Function, LeftAdultBiomarkersBiopsyCardiomyopathiesCardiovascular AgentsChemotaxis, LeukocyteFemaleHeart FailureHumansMaleMiddle AgedMultivariate AnalysisMyocarditisBiomarkersCardiovascular AgentsNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)EchocardiographyEndomyocardial biopsyInflammatory cardiomyopathyLeft ventricular dysfunctionMyocarditis

Identifiers

PMID25539624
OpenAlexW2011274072

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.